Coherus’ Pegfilgrastim Sales Fall $150m In 2021 As Firm Plans On-Body

Pegfilgrastim Revenues Set To Slide Again In 2022 Amid Challenging Market

 
• By Dean Rudge
  
A Businessperson Stopping Colorful Dominoes From Falling On Desk
Coherus is aiming to stop falling sales with new launches • Source: Alamy/Andriy Popov
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business